ProCE Banner Activity

KEYNOTE-146: Lenvatinib Plus Pembrolizumab as Early-Line Treatment of Advanced Endometrial Cancer

Slideset Download
Conference Coverage
Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.

Released: June 05, 2020

Expiration: June 04, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono